论文部分内容阅读
为探讨P53,NM23,P16 基因产物在肺癌表达的临床意义,采用链霉抗生物素蛋白－ 过氧化物酶(S－ P) 快速免疫组化法检测了64 例NSCLC( 非小细胞型肺癌)患者肺癌组织及配对淋巴结组织三种基因产物的表达.结果显示: 肺癌组织P53 表达阳性率达76－56％ (49/64),NM23 蛋白阳性为60－94％ (39/64),P16 蛋白缺失率48－4％(31/64) .51－56％ 呈阳性表达,阳性表达中很可能存在突变蛋白.P16 蛋白表达与NSCLC的淋巴结转移关系密切( P＜ 0－05) .NM23 蛋白表达与肺癌淋巴结转移没有相关性.在肺癌淋巴结转移灶,42－86％ P16 蛋白阳性,54－29％ NM23 蛋白阳性,P53 则无1 例阳性表达,表明三者在NSCLC 的作用环节,作用机制可能不同.结论:P53 ,NM23,P16 基因异常改变与肺癌发生或发展关系密切,P53 基因改变在肺癌可能是一个早发事件,P16 基因变化可能属于迟发事件,NM23 基因在肺癌淋巴结转移灶的高表达,提示其在肺癌发展,转移中可能起着不同作用.“,”To study the clinical significance of the expression of p53,nm23 and p16 gene in the patients of lung cancer,streptavidin-peroxidase conjugated method(S-P) was used to detect the expression of these three gene products in the lung cancer tissues and paired lymph nodes of 64 NSCLC patients.The results showed that the positive expression rates of p53 and nm23 were 76.56%(49/64) and 60.94%(39/64) in the lung cancer tissues respectively.The positive expression rate of p16 was 51.60%(33/64),in which might exist mutational proteins.The lymph node metastasis was significantly correlated to p16 protein expression( P <0.05) and uncorrelated to nm23 protein expression.In the metastatic lymph nodes, the positive expression rates of nm23 and p16 were 54.29% and 42.86% respectively,but all of the p53 protein expression was negative.The results suggest that the mechanism of the action of these three genes may be different in NSCLC.The abnormal changes of p53,nm23 and p16 genes are closely related to the pathogenesis of lung cancer.p53 gene changes possibly is an early stage case and p16 gene changes may be an important event in the late phase of NSCLC.High expression of nm23 in lung cancer lymph node metastatic indicates that nm23 may play different roles in the development and metastasis of lung cancer.